Ling Xu

3.0k total citations
129 papers, 2.3k citations indexed

About

Ling Xu is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Ling Xu has authored 129 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Cancer Research, 60 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Ling Xu's work include Breast Cancer Treatment Studies (43 papers), HER2/EGFR in Cancer Research (32 papers) and MicroRNA in disease regulation (14 papers). Ling Xu is often cited by papers focused on Breast Cancer Treatment Studies (43 papers), HER2/EGFR in Cancer Research (32 papers) and MicroRNA in disease regulation (14 papers). Ling Xu collaborates with scholars based in China, Australia and United States. Ling Xu's co-authors include Jerry L. Nadler, Rama Natarajan, Hua Zhang, Chunxiang Zhang, Jian Yang, Yunhui Cheng, Xiaojun Liu, Yujie Chen, Noe Gonzales and Yusheng Zheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Ling Xu

125 papers receiving 2.3k citations

Peers

Ling Xu

ONCOL

RNMI

SURGE

Longhua Chen China

Jianming Zheng China

Jianfei Huang China

Yongxiang Xia China

Gloria Peiró Spain

Tomohiro Arita Japan

Gregor Krings United States

Shinichi Sakamoto Japan

Yao Yu United States

Longhua Chen China

Ling Xu

1.5k ×1.3

1.0k ×0.9

516 ×1.0

ONCOL

157 ×0.6

RNMI

190 ×0.8

SURGE

Citations per year, relative to Ling Xu Ling Xu (= 1×) peers Longhua Chen

Countries citing papers authored by Ling Xu

Since Specialization

Citations

This map shows the geographic impact of Ling Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Xu more than expected).

Fields of papers citing papers by Ling Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Xu. The network helps show where Ling Xu may publish in the future.

Co-authorship network of co-authors of Ling Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Xu. A scholar is included among the top collaborators of Ling Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Xu. Ling Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Jiulong, Weihong Chen, Ling Xu, et al.. (2024). The safety of trastuzumab deruxtecan (DS‐8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single‐arm meta‐analysis. Cancer. 130(17). 2968–2977. 6 indexed citations

Zhao, Ting, et al.. (2024). Dual‑regulated oncolytic adenovirus carrying ERCC1‑siRNA gene possesses potent antitumor effect on ovarian cancer cells. Molecular Medicine Reports. 30(1). 3 indexed citations

Yin, Lei, Linlin Ma, Caixia Wu, et al.. (2024). Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using 18F-FDG PET/CT imaging. Cancer Imaging. 24(1). 166–166. 3 indexed citations

Ding, Mao, et al.. (2023). Comparison of adverse effects of anti-tumor therapy for breast cancer shortly after COVID-19 diagnosis vs. the control period. Frontiers in Oncology. 13. 1203119–1203119. 1 indexed citations

Zhang, H, et al.. (2023). [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].. PubMed. 55(2). 243–253. 2 indexed citations

Liu, Yinhua, et al.. (2023). Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer. Journal of Cancer Research and Clinical Oncology. 149(13). 12333–12353. 3 indexed citations

Wang, Yang, et al.. (2022). [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].. PubMed. 54(5). 853–862. 2 indexed citations

Zhang, H, et al.. (2021). [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].. PubMed. 59(3). 222–227. 1 indexed citations

Xu, Ling, et al.. (2021). Surgery plus chemotherapy versus chemotherapy alone in primary intestinal lymphoma: a meta-analysis. Journal of International Medical Research. 49(11). 3619117773–3619117773. 3 indexed citations

10.

Yi, Yan, Hanfang Jiang, Ling Xu, et al.. (2020). [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].. PubMed. 52(2). 254–260. 7 indexed citations

11.

Qi, Ji, et al.. (2019). Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis. SHILAP Revista de lepidopterología. 3 indexed citations

12.

Wang, Yi, Jie Chen, Yanji Luo, et al.. (2018). Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media & Molecular Imaging. 2018. 1–10. 3 indexed citations

13.

Xu, Ling, et al.. (2018). [Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer].. PubMed. 98(12). 907–911. 2 indexed citations

14.

Zhang, Hong, Shuang Zhang, Qian Liu, et al.. (2015). [Analysis on clinical and pathological characteristics of 66 patients with stage IV breast cancer].. PubMed. 53(12). 935–40. 2 indexed citations

15.

Liu, Shiwei, Xuening Duan, Ling Xu, et al.. (2015). Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 154(2). 239–249. 29 indexed citations

16.

Liu, Shiwei, Xuening Duan, Ling Xu, et al.. (2015). Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy. Tumor Biology. 37(4). 4873–4881. 10 indexed citations

17.

Zhang, Chi, Xuening Duan, Ling Xu, et al.. (2012). Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Breast Cancer Research and Treatment. 136(3). 739–748. 14 indexed citations

18.

Xu, Ling, Wei Peng, Xiaohong Wang, et al.. (2011). MRI characteristics of ductal carcinoma in situ of the breast. Zhonghua fangshexian yixue zazhi. 45(2). 159–163. 1 indexed citations

19.

Xu, Ling. (2005). Experimental study on reversion effect of elemene on multidrug resistance of human gastric cancer cell line. 4 indexed citations

20.

Xu, Ling. (2001). Effect of Xiaotan Sanjie Recipe on Expression of ICAM-1 in Gastric Carcinoma. Liaoning zhongyi zazhi. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact